Thermo Fisher Q3 revenue, adj profit beat estimates after new product launches

By Reuters News


Overview

  • Lab equipment supplier's Q3 revenue rose 9%, beating analyst expectations

  • Adjusted EPS for Q3 grew 15%, beating analyst expectations

  • Company cites growth strategy, new products, and execution as drivers of results


Outlook

  • Thermo Fisher will provide updated 2026 financial guidance during its earnings call


Result Drivers

  • NEW PRODUCTS - Co said Q3 results were driven by launches of new products including Orbitrap Isora mass spectrometer, EMPAD G2 electron detector, EliA CTD 13 Screen autoimmune test, and Ion 560 sequencing chip

  • COMMERCIAL ENGINE - Co said it strengthened its commercial engine and deepened customer partnerships, including new initiatives with Mayo Clinic and opening an AI-Automation Innovation Center in South Korea

  • EXECUTION - Co attributed results to execution enabled by its PPI Business System


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$12.14 bln

$11.95 bln (21 Analysts)

Q3 Adjusted EPS

Beat

$6.68

$6.40 (22 Analysts)

Q3 EPS

$4.64

Q3 Adjusted Net Income

Beat

$2.48 bln

$2.38 bln (15 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 27 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Thermo Fisher Scientific Inc. is $705.00, about 2.6% above its October 20 closing price of $687.37

  • The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 19 three months ago


Reuters Recommended Reads

  • Oct 20 - 3M tops Q3 adjusted EPS estimates, raises guidance

  • Oct 20 - Intuitive Surgical Q3 results top estimates on higher da Vinci system placements


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.